111 related articles for article (PubMed ID: 37302280)
1. Development of a novel modified vaccine (TheraVac
Masud Alam M; Huang Y; Oppenheim JJ; Yang D
Cytokine; 2023 Sep; 169():156270. PubMed ID: 37302280
[TBL] [Abstract][Full Text] [Related]
2. Reactive Oxygen Species-Sensitive Biodegradable Mesoporous Silica Nanoparticles Harboring TheraVac Elicit Tumor-Specific Immunity for Colon Tumor Treatment.
Huang Y; Nahar S; Alam MM; Hu S; McVicar DW; Yang D
ACS Nano; 2023 Oct; 17(20):19740-19752. PubMed ID: 37831945
[TBL] [Abstract][Full Text] [Related]
3. Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.
Nie Y; Yang D; Trivett A; Han Z; Xin H; Chen X; Oppenheim JJ
Sci Rep; 2017 Oct; 7(1):14186. PubMed ID: 29079801
[TBL] [Abstract][Full Text] [Related]
4. A Therapeutic Vaccine in Combination with Cyclic GMP-AMP Cures More Differentiated Melanomas in Mice.
Alam MM; Gower T; Jiang M; Oppenheim JJ; Yang D
J Immunol; 2023 May; 210(9):1428-1436. PubMed ID: 36947147
[TBL] [Abstract][Full Text] [Related]
5. Regression and Eradication of Triple-Negative Breast Carcinoma in 4T1 Mouse Model by Combination Immunotherapies.
Nahar S; Huang Y; Nagy BA; Zebala JA; Maeda DY; Rudloff U; Oppenheim JJ; Yang D
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190294
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic vaccine to cure large mouse hepatocellular carcinomas.
Han Z; Yang D; Trivett A; Oppenheim JJ
Oncotarget; 2017 Aug; 8(32):52061-52071. PubMed ID: 28881713
[TBL] [Abstract][Full Text] [Related]
7. Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy.
Schetters STT; Rodriguez E; Kruijssen LJW; Crommentuijn MHW; Boon L; Van den Bossche J; Den Haan JMM; Van Kooyk Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690667
[TBL] [Abstract][Full Text] [Related]
8. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
9. HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways.
Alam MM; Yang D; Trivett A; Meyer TJ; Oppenheim JJ
Front Immunol; 2018; 9():2982. PubMed ID: 30619338
[TBL] [Abstract][Full Text] [Related]
10. Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer.
Zhu L; Zhang X; Chen X; Yang D; Nie Y; Pan R; Li L; Wang C; Gui H; Chen S; Jing Q; Wang M; Nie Y
Biochem Biophys Res Commun; 2023 Apr; 653():106-114. PubMed ID: 36868074
[TBL] [Abstract][Full Text] [Related]
11. A cell-laden hydrogel as prophylactic vaccine and anti-PD-L1 amplifier against autologous tumors.
Li J; Yan Y; Zhang P; Ding J; Huang Y; Jin Y; Li L
J Control Release; 2022 Nov; 351():231-244. PubMed ID: 36122899
[TBL] [Abstract][Full Text] [Related]
12. Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8
Chen CY; Ueha S; Ishiwata Y; Shichino S; Yokochi S; Yang D; Oppenheim JJ; Ogiwara H; Deshimaru S; Kanno Y; Aoki H; Ogawa T; Shibayama S; Matsushima K
Cancer Immunol Res; 2021 Oct; 9(10):1214-1228. PubMed ID: 34344641
[TBL] [Abstract][Full Text] [Related]
13. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
[TBL] [Abstract][Full Text] [Related]
14. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
16. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
17. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with HMGN1 and anti-CD4 depleting antibody reverses T cell exhaustion and exerts robust anti-tumor effects in mice.
Chen CY; Ueha S; Ishiwata Y; Yokochi S; Yang D; Oppenheim JJ; Ogiwara H; Shichino S; Deshimaru S; Shand FHW; Shibayama S; Matsushima K
J Immunother Cancer; 2019 Jan; 7(1):21. PubMed ID: 30696484
[TBL] [Abstract][Full Text] [Related]
19. Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Odunsi A; McGray AJR; Miliotto A; Zhang Y; Wang J; Abiola A; Eppolito C; Huang RY
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177175
[TBL] [Abstract][Full Text] [Related]
20. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
